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Adult respiratory distress syndrome due to Chlamydia 
pneumoniae in a young adult 
P. PANAGOU*, S. TSIPRA* AND D. BOUROS’~ 
Departments of Pneumonology, *Army General Hospital, Athens and j-Medical School, University of Crete, 
Heraklion, Greece 
A case of life-threatening Chlamydia TWAR pneumonia complicated by encephalitis in a young, previously 
healthy adult is described. The patient presented with full blown adult respiratory distress syndrome and 
required prolonged ventilatory support and rigorous antibiotic and supportive care. He recovered fully 
without any neurologic sequelae. Chlamydia pneumoniae pneumonia should be included in the differential 
diagnosis of the severe community acquired pneumonia, because if properly sought and adequately treated, 
may have an excellent outcome. 
Introduction 
About 10% of pneumonia cases admitted to hospi- 
tal have been shown to be associated with TWAR 
infection, and of these 70-90% are mild with short- 
term disability. If these are not treated, there may be 
prolonged symptoms with malaise and cough extend- 
ing for several months, but a serious life-threatening 
illness in a normal young host has not been described 
to date. Although severe episodes and even deaths 
have been reported in patients with pre-existing 
severe chronic diseases (1) and in the elderly (2), no 
cases of severe pneumonia in normal hosts due to 
TWAR have been reported. Attempts to diagnose 
this pathogen have been rarely, if ever, performed (3). 
This report describes a case of severe Chlanzydia 
pneumoniae community-acquired pneumonia with 
adult respiratory distress syndrome. A simple diag- 
nostic methodology that is useful in the everyday 
clinical practice is also described. 
Case Report 
A 42-year-old man of previous good health was 
admitted to the emergency room in acute respiratory 
distress. A week previously, he had suffered a com- 
mon cold-like illness with headaches, malaise, and 
generalized weakness, without fever. For the previous 
4 days, he had experienced high fever (39°C) with 
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chills, sweats and diarrhoea (6 in 24 h). Physical 
examination revealed an ill-appearing, febrile, mark- 
edly tachypnoeic man with tachycardia, normal 
blood pressure and a few crackles over the right 
upper and left lower lung fields. He appeared con- 
fused, disoriented, with seriously diminished mental 
status, and had bouts of grand ma1 seizures, due to 
probable encephalitis. Arterial blood gas determina- 
tion with an AO, of 0.5 was compatible with acute 
hypoxaemic respiratory failure (PaO, 48 mmHg, 
PaCO, 40 mmHg, pH 7.32), so he was intubated 
receiving controlled mechanical ventilation with 
100% O,, tidal volume of 10 ml kg - ’ and 10 cm H,O 
PEEP on the first day. The patient had a severe acute 
lung injury (lung injury score of 10) and he fulfilled 
the criteria of its expanded definition (4); namely he 
had an associated clinical disorder (pneumonia) and 
a non-pulmonary organ failure (encephalitis). Chest 
X-ray revealed a dense right upper lobe infiltrate with 
concomitant fluffy nodular opacities scattered 
throughout both lung fields. 
Laboratory studies demonstrated a haemoglobin 
level of 14.5 g dl- ‘, haematocrit of 44%, white blood 
cell count of 7300 cells mm - 3, with 89% neutrophils, 
8% lymphocytes and 2% monocytes. The erythrocyte 
sedimentation rate was elevated to 67 mm h- ‘. 
Aspartase aminotransferase (ASAT) was 245 IU l- ‘, 
alanine aminotranferase (ALAT) 69 IU 1~ ‘, gamma 
glutamyltranferase (yGT) 92 IU 1 - i and lactic dehy- 
drogenase (LDH) 1060 IU I- i. Renal biology and 
serum Na’ were normal. He was put on empirical 
treatment proposed for severe community-acquired 
pneumonia (5) including erythromycin 4 g i.v. along 
with cefotaxime 8 g i.v. daily, that was changed to 
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oral doxycycline for an additional lo-day period after 
diagnosis and clinical improvement. The patient 
required prolonged ventilatory support for the next 
few days, gradually improving and was success- 
fully weaned on the 12th hospital day. He made a 
complete recovery with no neurologic sequelae. 
Quantitative brush-protected-specimen cultures 
were non-diagnostic (sterile) for the presence of 
pathogenic bacteria, as well as blood cultures. Acute 
phase serum samples obtained on the 12th day of 
illness, showed an IgM antibody titer > l/80 (normal 
O&1/16) by indirect immunofluorescence (Bios, 
Germany) directed against the major outer mem- 
brane protein, of C. pneumonia being genus specific, 
while at the same time indirect immunofluorescence 
against Chlamydia psittaci was negative. The patient 
had a negative rheumatoid factor, so false positive 
reactions were excluded (broadly reactive IgM 
activities to all three chlamydial species were fre- 
quently the result of the presence of rheumatoid 
factor in the test sera). Chlamydia pneumoniae were 
identified concomitantly in nasopharyngeal swab 
specimen with C. pneumoniae specific monoclonal 
antibody, unconjugated (Cellabs, Australia). Acute 
and convalescent complement fixing antibodies were 
negative for Influenza A and B, Mycoplasma pneumo- 
niae, Parainfuenza type 1 and 3, Coxiella burnetti, 
and Chlamydiapsittaci (titer <l/SO. Indirect immuno- 
fluorescence was negative for Legionellapneumophila, 
serotypes l-6 (Viron, Switzerland). The patient 
denied any contact with birds by recreational or 
occupational exposure, and he had no history of 
recent urethritis. 
Discussion 
Chlamydia pneumoniae is now considered the third 
species of Chlamydia causing human disease, the 
other two being C. trachomatis and C. psittaci. There 
are two known serovariants, namely TWAR and 
IOL-207, of which TWAR is best understood. The 
serological profile of the present patient is indicative 
of an acute infection rather than a re-infection, 
because IgM antibodies at re-infection may not 
appear or exist at low titers (6). Re-infection appears 
to be generally, although not always, associated with 
milder illness than a first infection. A high antibody 
titer as early as the 12th day of hospital stay (19th 
day of illness) is not unusual (7) and may in fact 
represent an index of clinical severity. Severe life- 
threatening pneumonia due to Chlamydia TWAR 
has been described by Marrie et al., where in their 
series, four patients were mechanically ventilated 
and two died, but the hosts were old with severe 
comorbidity (1). 
The therapeutic regimen contained an erythromy- 
tin plus a third generation cephalosporin, because 
the authors wanted a broad spectrum antibiotic 
coverage in such a serious condition. Furthermore it 
is also known that copathogens are usually present 
along with Chlamydia TWAR (8). Even though the 
initial presentation was suggestive of Legionella 
infection, this seemed unlikely later in view of the 
serological and electrolytic profiles. Although mental 
status changes can occur after severe hypoxaemia, 
the combination of seizures with the former is sug- 
gestive of encephalitis. Central nervous system mani- 
festations are not unusual with C. pneumoniae 
infections and in one study (9), 38% of patients 
showed mental status changes. Chlamydia pneumo- 
niae like Mycoplasma pneumoniae may be compli- 
cated by extrapulmonary manifestations as in the 
present case, and so far erythema nodosum, thyroid- 
itis, encephalitis and the Guillain-Barre syndrome 
have been described. These have been attributed to 
the 60 kDa protein of C. pneumoniae, which is a 
delayed-type hypersensitivity antigen (8). The chest 
X-ray appearance showing a lobar distribution found 
predominantly in bacterial pneumonias confirms 
previous findings that there are not clinical, radio- 
graphic or laboratory features characteristic of 
atypical bacterial infection in hospitalized patients. 
The microimmunofluorescence test using C. 
pneumoniae specific antigen (TW-183) is considered 
the gold standard for diagnosis, but it is restricted to 
reference and research laboratories and is not com- 
mercially available. Furthermore, it has been shown 
recently in some studies to have cross-reactions with 
the other Chlamydia species, so there is a need for a 
more objective and more accurate test for serodiag- 
nosis, because it is inadequate (10). The combination 
of high genus specific antibody titer along with the 
negative serology for C. psittaci and the direct iden- 
tification of Chlamydia TWAR in nasopharyngeal 
swabs established the diagnosis. Although asympto- 
matic carriage in the nasopharynx from a previous 
infection is a rare possibility, this seems unlikely 
considering the serological profile of the present 
patient. Furthermore, history and the relative rarity 
of C. psittaci pneumonia strongly indicted the diag- 
nosis. On the other hand, molecular techniques are 
now becoming available, but they need to be vali- 
dated in terms of sensitivity and specificity. Culture 
of this fastidious organism is considered the gold 
standard for diagnosis, but requires some time (3 
days), may suffer in terms of sensitivity, and needs 
expertise and equipment found only in specialized 
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laboratories. The authors think the simple diagnostic 
procedure used in this report can be useful in 
everyday practice for an initial identification of 
C. pneumoniae infection. 
In conclusion, the above case illustrates that C. 
pneumoniae can be a cause of severe illness in healthy 
adults and should be included in the differential 
diagnosis of severe pneumonia. 
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